Research To Practice | Oncology Videos

Latest Episodes:

Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 Mutations (Companion Faculty Lecture) Aug 11, 2025

Show notes

Featuring a slide presentation and related discussion from Dr Jorge Cortes, including the following topics:

Oncology Today with Dr Neil Love: Perspectives on New Datasets in FLT3- and IDH1/2-Mutant Acute Myeloid Leukemia — Dr Cortes (0:00)

CME information and select publications

Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances Aug 08, 2025

Show notes

Featuring perspectives from Dr Benjamin Levy, including the following topics:

Introduction: The Boards (0:00)
Immune Checkpoint Inhibition for Localized Non-Small Cell Lung Cancer (NSCLC) (11:43)
Immunotherapy for Metastatic NSCLC (24:41)
Antibody-Drug Conjugates (33:46)
Novel Bispecific Antibodies (42:08)
Journal Club with Dr Levy (51:28)

CME information and select publications

Multiple Myeloma — Optimizing the Selection of First-Line Therapy Aug 07, 2025

Show notes

Featuring perspectives from Prof Xavier Leleu and Dr Peter Voorhees, including the following topics:

Introduction: Myeloma Time Capsule (0:00)
Smoldering Myeloma (7:21)
Autologous Stem Cell Transplant (ASCT) Eligible Patients (13:05)
ASCT Ineligible Patients (32:18)
Subcutaneous Anti-CD38 Antibodies (47:24)
Special Considerations (54:27)

CME information and select publications

Multiple Myeloma | Peter Voorhees, MD Aug 06, 2025

Show notes

Optimizing the Selection of First-Line Therapy for Patients with Multiple Myeloma | Faculty Presentation — Peter Voorhees, MD

CME information and select publications

Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates Aug 03, 2025

Show notes

Featuring an interview with Dr Erika Hamilton, including the following topics:

Optimal selection and sequencing of available antibody-drug conjugates for HR-positive metastatic breast cancer (0:00)
- Bardia A et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. J Clin Oncol 2025;43(3):285-96. Abstract
- Pistilli B et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival from the Phase III TROPION-Breast01 trial. ESMO Virtual Plenary 2025;Abstract VP1-2025.
First-line use of sacituzumab govitecan in combination with pembrolizumab for advanced triple-negative breast cancer (8:02)
- Tolaney SM et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. ASCO 2025;Abstract LBA109.
Ongoing trials evaluating datopotamab deruxtecan in earlier lines of therapy (12:06)
- Dent RA et al. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol 2023;19(35):2349-59. Abstract
- McArthur HL et al. TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer. Ther Adv Med Oncol 2025;17:17588359251316176. Abstract
- Bardia A et al. TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol 2024;16:17588359241248336. Abstract
- Schmid P et al. TROPION-Breast05: A randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol 2025;17:17588359251327992. Abstract
Available data with and ongoing trials of sacituzumab tirumotecan for HR-positive, HER2-negative and triple-negative breast cancer (16:53)
- Yin Y et al. Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. ASCO 2025;Abstract 1019.
- Xu B et al. Sacituzumab tirumotecan in patients with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the Phase III Opti-TROP-Breast01 study. ASCO 2024;Abstract 104.
- Yin Y et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: A randomized phase 3 trial. Nat Med 2025;31(6):1969-1975. Abstract
- Garrido-Castro AC et al. SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic HR+/HER2-negative breast cancer. ASCO 2024;Abstract LBA1004.

CME information and select publications

Gynecologic Cancers — Year in Review Series on Relevant New Datasets and Advances Aug 02, 2025

Show notes

Featuring perspectives from Prof Susana Banerjee and Dr Ursula Matulonis, including the following topics:

Introduction: Tale of Two Cities — ASCO 2025 (0:00)
Ovarian Cancer (11:20)
HER2-Positive Gynecologic Cancers (31:28)
Endometrial Cancer (40:16)
Cervical Cancer (51:14)

CME information and select publications

Endometrial and Cervical Cancer | Susana Banerjee, MBBS, MA, PhD Aug 01, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gynecologic Cancers | Faculty Presentation 2: Endometrial Cancer and Cervical Cancer — Susana Banerjee, MBBS, MA, PhD

CME information and select publications

Ovarian Cancer | Ursula Matulonis, MD Jul 31, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gynecologic Cancers | Faculty Presentation 1: Ovarian Cancer — Ursula Matulonis, MD

CME information and select publications

Oncology Nursing Update: Prostate Cancer — An Interview with Ms Kathleen D Burns on the Current Treatment Paradigm and New Approaches to Patient Care Jul 30, 2025

Show notes

Featuring an interview with Ms Kathleen D Burns, including the following topics:

Case: A man in his early 70s with metastatic hormone-sensitive prostate cancer who received an androgen receptor inhibitor in combination with androgen deprivation therapy (0:00)
Case: A man in his early 70s with metastatic castration-resistant prostate cancer (mCRPC) who received olaparib in combination with abiraterone (23:20)
Case: A man in his mid 70s with mCRPC who received lutetium Lu 177 vipivotide tetraxetan (33:44)

NCPD information and select publications

Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management Jul 29, 2025

Show notes

Featuring an interview with Dr Hope S Rugo, including the following topics:

Pharmacologic features of antibody-drug conjugates (ADCs) and implications for their efficacy and toxicity in HR-positive breast cancer (0:00)
Clinical and biological factors influencing the sequencing of approved ADCs for HR-positive and triple-negative metastatic breast cancer (4:03)
Management of common toxicities with approved ADCs (10:48)
Sacituzumab govitecan as first-line therapy for metastatic triple-negative breast cancer (18:17)
Trastuzumab deruxtecan in combination with pertuzumab as first-line therapy for HER2-positive metastatic breast cancer (21:09)

CME information and select publications